Evidence map›Paper›PMID 24705504›Full record

ArticlePloS one2014

Gene expression profiling of mitochondrial oxidative phosphorylation (OXPHOS) complex I in Friedreich ataxia (FRDA) patients.

Mohammad Hossein Salehi, Behnam Kamalidehghan, Massoud Houshmand, Goh Yong Meng, Majid Sadeghizadeh, Omid Aryani, Shahriar Nafissi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Systems-level analyses dissociate genetic regulators of reactive oxygen species and energy production.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Subcellular Performance of Nanoparticles in Cancer Therapy.International journal of nanomedicine · 2020
    Review
  14. Article
  15. Article
  16. Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Article
  17. An N-Ethyl-N-Nitrosourea (ENU)-Induced Tyr265Stop Mutation of the DNA Polymerase Accessory Subunit Gamma 2 (Polg2) Is Associated With Renal Calcification in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Mohammad Hossein SalehiDepartment of Molecular Genetics, Tarbiat Modares University, Tehran, Iran.
Behnam KamalidehghanDepartment of Pharmacy, Faculty of Medicine, University of Malaya (UM), Kuala Lumpur, Malaysia.
Massoud HoushmandDepartment of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran; Department of Medical Genetics, Special Medical Center, Tehran, Iran.
Goh Yong MengDepartment of Preclinical Sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Selangor, Malaysia; Institute of Tropical Agriculture, Universiti Putra Malaysia, Selangor, Malaysia.
Majid SadeghizadehDepartment of Molecular Genetics, Tarbiat Modares University, Tehran, Iran.
Omid AryaniDepartment of Medical Genetics, Special Medical Center, Tehran, Iran.
Shahriar NafissiDepartment of Neurology, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.
Tarbiat Modares University · IRNational Institute of Genetic Engineering and Biotechnology · IRShariati Hospital · IRUniversiti Putra Malaysia · MYUniversity of Malaya · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Friedreich ataxia (FRDA) is the most frequent progressive autosomal recessive disorder associated with unstable expansion of GAA trinucleotide repeats in the first intron of the FXN gene, which encodes for the mitochondrial frataxin protein. The number of repeats correlates with disease severity, where impaired transcription of the FXN gene results in reduced expression of the frataxin protein. Gene expression studies provide insights into disease pathogenicity and identify potential biomarkers, an important goal of translational research in neurodegenerative diseases. Here, using real-time PCR (RT-PCR), the expression profiles of mitochondrial (mtDNA) and nuclear DNA (nDNA) genes that encode for the mitochondrial subunits of respiratory oxidative phosphorylation (OXPHOS) complex I in the blood panels of 21 FRDA patients and 24 healthy controls were investigated. Here, the expression pattern of mtDNA-encoded complex I subunits was distinctly different from the expression pattern of nDNA-encoded complex I subunits, where significant (p<0.05) down-regulation of the mitochondrial ND2, ND4L, and ND6 complex I genes, compared to controls, were observed. In addition, the expression pattern of one nDNA-encoded gene, NDUFA1, was significantly (p<0.05) down-regulated compared to control. These findings suggest, for the first time, that the regulation of complex I subunit expression in FRDA is complex, rather than merely being a reflection of global co-regulation, and may provide important clues toward novel therapeutic strategies for FRDA and mitochondrial complex I deficiency.

Indexed as

Gene Expression ProfilingGenes, MitochondrialAdolescentAdultCase-Control StudiesChildChild, PreschoolElectron Transport Complex IFemaleFriedreich AtaxiaGene Expression RegulationHumansMaleYoung AdultElectron Transport Complex I

Identifiers

PMID24705504
PMCPMC3976380
OpenAlexW2007141625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.